49 research outputs found
Differential effects of TRPV1 receptor ligands against nicotine-induced depression-like behaviors
Antidepressants and Changes in Concentration of Endocannabinoids and N-Acylethanolamines in Rat Brain Structures
The fatty acid amide hydrolase inhibitor URB597 modulates serotonin-dependent emotional behaviour, and serotonin1A and serotonin2A/C activity in the hippocampus
Differences between direct cannabinoid agonists and FAAH inhibitors on antidepressant-like behavioural and serotonin-modulatory activity
Interazione tra sistema cannabinoide e serotoninergico: implicazioni farmacologiche e cliniche per il trattamento della depressione
XV Congresso della Società Italiana di Neuropsicofarmacologia
Volume degli atti S16-2, -(Poster)
Promotion of non-rapid eye movement sleep and activation of reticular thalamic neurons by a novel MT2 melatonin receptor ligand
Melatonin activates two brain G-protein coupled receptors, MT1 and MT2 , whose differential roles in the sleep–wake cycle remain to be
defined. The novel MT2 receptor partial agonist, N-{2-[(3-methoxyphenyl) phenylamino] ethyl} acetamide (UCM765), is here shown to
selectively promote non-rapid eye movement sleep (NREMS) in rats and mice. The enhancement ofNREMSby UCM765 is nullified by the
pharmacological blockade or genetic deletion ofMT2 receptors.MT2 , but notMT1 , knock-out mice show a decrease inNREMScompared
to the wild strain. Immunohistochemical labeling reveals thatMT2 receptors are localized in sleep-related brain regions, and notably the
reticular thalamic nucleus (Rt). Microinfusion of UCM765 in the Rt promotes NREMS, and its systemic administration induces an
increase in firing and rhythmic burst activity of Rt neurons, which is blocked by the MT2 antagonist 4-phenyl-2-propionamidotetralin.
Since developing hypnotics that increase NREMS without altering sleep architecture remains a medical challenge, MT2 receptors may
represent a novel target for the treatment of sleep disorders
Recommended from our members